Online citations, reference lists, and bibliographies.

Modularity Of Osteoclast Behaviour And “mode-specific” Inhibition Of Osteoclast Function

M. Zaidi
Published 1990 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
This study is part of an attempt to understand the role of specific cellular activities in the bone resorptive process. Experiments were performed whereby known pharmacological agents were used to inhibit individual modes of osteoclastic activity, such as motility and secretion. The effects of such treatments on bone resorption were assessed by quantitative scanning electron microscopy. The compounds included colchicine, which was used to inhibit osteoclast motility; molybdate ions which were used to selectively inhibit the catalytic activity of secreted acid phosphatase, and omeprazole which was employed to inhibit the secretion of hydrogen ions. All compounds inhibited osteoclastic bone resorption, but singularly affected defined modes of activity. These findings suggest that each mode of osteoclastic activity is essential for the bone resorptive process, and that “mode-specific” inhibition may provide a means whereby excessive activity of the osteoclast can be regulated in disease.
This paper references
The effects of H+-K+-ATPase and carbonic anhydrase inhibitors on hormone-stimulated bone resorption in vitro. In: Cell mediated calcification and matrix vesicles
H. K. Vaananen (1986)
10.1113/jphysiol.1990.sp018242
Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption.
Baljit S. Moonga (1990)
The effect of extracellular calcium elevation on the morphology and function of isolated osteoclasts
H. K. Datta (1989)
10.1002/jcp.1041320112
Hormonal regulation of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone.
Timothy J. Chambers (1987)
10.1016/0006-291X(89)92405-4
Inhibition of osteoclastic acid phosphatase abolishes bone resorption.
M. Zaidi (1989)
10.1113/expphysiol.1988.sp003168
Effects of peptides from the calcitonin genes on bone and bone cells.
M. Zaidi (1988)
The effects of H + - K + - ATPase and carbonic anhydrase inhibitors on hormone - stimulated bone resorption in vitro
H. K. Vaananen (1986)
10.1126/science.2528207
Osteoclastic bone resorption by a polarized vacuolar proton pump.
H. Blair (1989)
10.1677/joe.0.1260473
Evidence that the action of calcitonin on rat osteoclasts is mediated by two G proteins acting via separate post-receptor pathways.
M. Zaidi (1990)
Calcium inhibits cell-matrix adhesion
M. W. Makgoba (1990)
10.1097/00003086-198806000-00033
Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts.
G. Vaes (1988)
10.1002/path.1711360104
Calcitonin alters behaviour of isolated osteoclasts.
Timothy J. Chambers (1982)
10.1007/BF02556841
Omeprazole, a specific inhibitor of H+−K+-ATPase, inhibits bone resorptionin vitro
J. Tuukkanen (2007)
10.1016/0006-2952(85)90023-1
Studies on the mechanism of action of omeprazole.
D. Jeannette Keeling (1985)
10.1016/8756-3282(90)90058-7
Oxygen derived free radicals in osteoclasts: the specificity and location of the nitroblue tetrazolium reaction.
L. Key (1990)



This paper is referenced by
10.1177/875512250802400404
Safety of Proton Pump Inhibitors in Community-Dwelling Older Adults
Adrienne J. Lindblad (2008)
10.1111/cid.12455
Proton Pump Inhibitors and the Risk of Osseointegrated Dental Implant Failure: A Cohort Study
Xixi Wu (2017)
10.1007/s00391-012-0374-7
Osteoporosis and polypharmacy
M Gosch (2012)
10.1097/MEG.0b013e328348a56a
Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis
Xiaofei Ye (2011)
10.1111/jcpe.12506
Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae.
Ahmed Al Subaie (2016)
10.1089/ten.a.2007.0086
No increased bone formation around alendronate or omeprazole loaded bioactive bone cements in a femoral defect.
Esther W H Bodde (2008)
10.1007/BF00188348
A quantitative description of components of in vitro morphometric change in the rat osteoclast model: relationships with cellular function
Mone Zaidi (1992)
10.1111/j.1742-1241.2008.01883.x
Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients.
Alper Kırkpantur (2009)
10.1111/nyas.13861
Regulatory actions of 3',5'-cyclic adenosine monophosphate on osteoclast function: possible roles of Epac-mediated signaling.
Kamalan Jeevaratnam (2018)
10.1242/jcs.00935
Endocytic trafficking in actively resorbing osteoclasts
Gudrun Stenbeck (2004)
10.12890/2019_001279
Mandibular Osteonecrosis Associated with Antacid Therapy (Esomeprazole)
Simone Marconcini (2019)
10.1007/s00198-009-0891-4
Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates
Frank de Vries (2009)
10.3821/1913701X2008141S19TSOPPI20CO2
The Safety of Proton Pump Inhibitors
Adrienne J. Lindblad (2008)
Atividade osteoclástica na superfície de hidroxiapatite nano e microestruturada modulada pela presença de inibidores da bomba de protões
Hélder Tiago Gomes Silva (2014)
10.1155/2015/413097
Pantoprazole Decreases Cell Viability and Function of Human Osteoclasts In Vitro
Markus Prause (2015)
10.3760/cma.j.issn.0366-6999.20132862
Iloprost inhibits fracture repair in rats
Ali Dogan (2014)
10.1155/2010/597641
Osteogenic Activity of Locally Applied Small Molecule Drugs in a Rat Femur Defect Model
Jessica Cottrell (2010)
10.1152/ajpcell.00551.2003
Prostaglandin E2 activates outwardly rectifying Cl(-) channels via a cAMP-dependent pathway and reduces cell motility in rat osteoclasts.
Fujio Okamoto (2004)
10.1002/phar.1299
Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.
James A Tjon (2013)
Pantoprazole , a proton pump inhibitor , delays bone remodeling during fracture healing in mice
2 Scheuer (2011)
Hip Fracture Long-term Proton Pump Inhibitor Therapy and Risk of Correction
Y. Yang (2006)
10.1586/17474124.3.1.15
Esomeprazole: a proton pump inhibitor
Ravi Vachhani (2009)
10.1370/afm.1243
Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies
Chun-Sick Eom (2011)
10.22037/ghfbb.v1i3.33
Effect of omeprazole on bone mineral density and frequency of osteopenia and osteoporosis
Homayoun Zojaji (2009)
10.1007/s00223-012-9601-x
Pantoprazole, a Proton Pump Inhibitor, Delays Fracture Healing in Mice
T. Histing (2012)
Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice
J.B. Vegger (2017)
10.1111/febs.12478
Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity.
João Costa-Rodrigues (2013)
10.1177/875512250702300504
Role of Proton Pump Inhibitors in Calcium Absorption, Bone Resorption, and Risk of Hip Fracture
Rabia Tahir (2007)
10.1016/j.injury.2014.05.005
Pantoprazole increases cell viability and function of primary human osteoblasts in vitro.
Markus Prause (2014)
10.5662/wjm.v1.i1.15
Risk of fracture and pneumonia from acid suppressive drugs.
Chun-Sick Eom (2011)
In vitro effects of pantoprazole on human osteoblasts and osteoclasts
Markus Prause (2016)
10.1159/000028183
Differences in pH-Dependent Activation Rates of Substituted Benzimidazoles and Biological in vitro Correlates
W. Kromer (1998)
See more
Semantic Scholar Logo Some data provided by SemanticScholar